Loading clinical trials...
Loading clinical trials...
A Phase I, Open Label, Single Sequence, Drug Interaction Study Evaluating Plasma GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects.
Conditions
Interventions
Raltegravir
GSK2248761
+1 more
Locations
1
United States
GSK Investigational Site
Buffalo, New York, United States
Start Date
April 1, 2010
Primary Completion Date
June 1, 2010
Completion Date
June 1, 2010
Last Updated
September 11, 2017
NCT06719310
NCT02831673
NCT02075593
NCT01231516
NCT02178592
NCT02415595
Lead Sponsor
ViiV Healthcare
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions